June 2026's Top Insider Owned Growth Companies
AAON, Inc. AAON | 0.00 |
The United States market has experienced a slight dip of 2.5% over the last week, yet it remains robust with a 20% increase over the past year and projected annual earnings growth of 19% in the coming years. In this context, growth companies with high insider ownership can be particularly appealing as they often align management's interests with those of shareholders, potentially positioning them well amidst fluctuating market conditions.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Uxin (UXIN) | 34.3% | 69.4% |
| Upstart Holdings (UPST) | 14.1% | 58.5% |
| McEwen (MUX) | 14.4% | 54.3% |
| Karman Holdings (KRMN) | 15.6% | 52.6% |
| Hesai Group (HSAI) | 17.5% | 27.4% |
| Figure Technology Solutions (FIGR) | 25.9% | 54.1% |
| Corcept Therapeutics (CORT) | 10.9% | 48.9% |
| Astera Labs (ALAB) | 10% | 29.4% |
| AppLovin (APP) | 27.2% | 22% |
| Allegiant Travel (ALGT) | 10% | 133.7% |
Below we spotlight a couple of our favorites from our exclusive screener.
AAON (AAON)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: AAON, Inc. and its subsidiaries engineer, manufacture, market, and sell air conditioning and heating equipment in the United States and Canada with a market cap of $10.60 billion.
Operations: The company's revenue segments include Basx at $385.14 million, AAON Oklahoma at $972.21 million, and AAON Coil Products at $368.19 million.
Insider Ownership: 15.9%
AAON, Inc. demonstrates strong growth potential with forecasted earnings growth of 28.4% annually, outpacing the US market's 18.5%. Despite high volatility in share price and recent insider selling, the company raised its 2026 revenue guidance to a substantial increase, supported by operational improvements and capacity expansion. Recent inclusion in the S&P Homebuilders Select Industry Index highlights its industry relevance. However, profit margins have declined from last year’s figures, indicating potential challenges ahead.
Youdao (DAO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Youdao, Inc. is an internet technology company offering online services in content, community, communication, and commerce in China with a market cap of approximately $1.42 billion.
Operations: The company's revenue is primarily derived from three segments: Smart Devices generating CN¥658.55 million, Learning Services contributing CN¥2.66 billion, and Online Marketing Services adding CN¥2.64 billion.
Insider Ownership: 20.9%
Youdao's earnings are forecast to grow significantly, at 52.4% annually, outpacing the US market. Despite a decline in profit margins from 2.6% to 1.2%, its revenue growth of 12.8% per year is expected to slightly surpass the US market average. Recent earnings showed a decrease in net income and EPS compared to last year, while no insider trading activity was reported over three months, indicating stable insider sentiment amidst financial challenges.
XPeng (XPEV)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: XPeng Inc. designs, develops, manufactures, and markets smart electric vehicles in China with a market cap of approximately $12.20 billion.
Operations: XPeng Inc. generates its revenue primarily from the auto manufacturing segment, which accounts for CN¥73.94 billion.
Insider Ownership: 20.9%
XPeng's growth trajectory is supported by its innovative product lineup and strategic market expansions. Recent achievements include the XPENG X9's standout performance in El Prix 2026, highlighting its advanced EV technology. Despite a net loss of CNY 1.78 billion in Q1 2026, XPeng aims for profitability within three years, with revenue expected to grow at 17.2% annually, above the US market average. Insider trading activity remains stable over recent months, reflecting consistent insider sentiment.
Make It Happen
- Access the full spectrum of 172 Fast Growing US Companies With High Insider Ownership by clicking on this link.
- Curious About Other Options? AI is about to change healthcare. These 127 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
